© PR Newswire
22.01.2026
ARX
LISTED
ASX
Study demonstrates effectiveness and economic value of Myriad™ in trauma and acute care surgery.
News Preview
AUCKLAND, New Zealand, Jan. 21, 2026 /PRNewswire/ -- Aroa Biosurgery Limited is pleased to announce that the latest publication from its ongoing prospective study, the Myriad Augmented Soft Tissue Reconstruction Registry (MASTRR), has been published in the Journal of Trauma and Injury.
MASTRR is the largest ongoing prospective, multicenter observa...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
TRVI
LISTED
NASDAQ
Trevi Therapeutics Announces Publication of Data from the Phase 2b IPF Chronic Cough Trial of nalbuphine ER in the Journal of the American Medical Association (JAMA)
News Preview
Statistically-significant reduction in the relative change from baseline in 24-hour objective cough frequency observed across all dose groups of nalbuphine ER at Week 6 with statistically-significant cough reduction as early as Week 2, the first time point measuredOver 60% of nalbuphine ER-treated patients achieved at least a 50% reduction in 24-h...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2026
SKNY
LISTED
CSE
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules
News Preview
VANCOUVER, BC / ACCESS Newswire / January 22, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce the completion of a study design for an ex vivo porcine skin investigation that is designed to evaluate whether novel transdermal agents can enhance the transdermal...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© ACCESS Newswire
22.01.2026
CLPT
LISTED
NASDAQ
ClearPoint Neuro Announces EU MDR Certification for ClearPoint Navigation Software Version 3.0.2, Expanding Access to the Latest Operating Room Navigation Platform in Europe
News Preview
SOLANA BEACH, CALIFORNIA / ACCESS Newswire / January 22, 2026 / ClearPoint Neuro, Inc. (NASDAQ:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced it has received EU MDR Certification for its ClearPoint Navigation Software Version 3.0.2."B...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
22.01.2026
LLY
LISTED
NYSE
ELI LILLY AND COMPANY INVESTOR ALERT: Scott+Scott Attorneys at Law LLP Investigates Eli Lilly and Company’s Directors and Officers for Breach of Fiduciary Duties – LLY
News Preview
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, is investigating whether the leadership of Eli Lilly and Company (“Eli Lilly”) (NYSE: LLY) breached their fiduciary duties to Eli Lilly and its shareholders.
CLICK HERE TO LEARN MORE
Scott+Scott is investigating whether members of...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
OSRH
LISTED
NASDAQ
Woori IO, an OSR Company, Highlights FDA Clarification on Non-Medical Wearables as a Catalyst for Accelerated Commercial Launch
News Preview
BELLEVUE, Wash., Jan. 22, 2026 /PRNewswire/ -- Woori IO, an OSR company developing next-generation noninvasive glucose monitoring technologies, today commented on the U.S. Food and Drug Administration's recent clarification regarding non-medical-grade wearable devices, noting that the FDA's position establishes a regulatory framework highly conduc...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
SCIB
LISTED
STO
Increased commitment in SciBase rights issue
News Preview
STOCKHOLM, Jan. 22, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB), a leading developer of AI-based diagnostic solutions for skin disorders, announces it has been informed that Life Science Investment Fund 1, one of SciBase larger shareholders have subscribed for their pro rata share of 5.0 percent in the ongoing rights issue. Fur...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2026
SKNY
LISTED
CSE
Ein neues Pflaster gegen starkes Übergewicht – und warum das für viele Menschen wichtig werden dürfte
News Preview
EQS-Media / 22.01.2026 / 14:56 CET/CEST
LIR Life Sciences Corp. (ISIN: CA50206C1005 | WKN: A41QA9) arbeitet an einer neuen Art von Medikamenten gegen starkes Übergewicht. Dabei geht es nicht um komplizierte Technik, sondern um eine einfache Idee: Statt Spritzen oder täglicher Tabletten soll ein Pflaster helfen, das man auf die Haut klebt. Dies......
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
TLRY
LISTED
TSX
Tilray Medical renforce sa présence sur le marché italien avec le lancement de Tilray Medical Italia et l’élargissement de son portefeuille de produits à base de cannabis thérapeutique
News Preview
NEW YORK et SAVONE, Italie, 22 janv. 2026 (GLOBE NEWSWIRE) -- Tilray Medical, une division de Tilray Brands, Inc. (« Tilray ») (Nasdaq : TLRY ; TSX : TLRY) et leader mondial du cannabis thérapeutique, qui favorise l’alliance thérapeutique entre les patients et les professionnels de santé afin de leur permettre de prendre des décisions éclairées e...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
HOTH
LISTED
NASDAQ
Hoth Therapeutics Delivers 100% Clinical Response with ~50% Reduction in Disease Severity in Open-Label PK Cohort of EGFR-Treated Cancer Patients
News Preview
Primary endpoint ARIGA improved by ~50% from baseline by Week 6, with all evaluable patients reaching low-severity disease; additional endpoints demonstrated ~34% improvement in oncology toxicity (CTCAE) and ~37% reduction in patient-reported pruritus.NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
HCTI
LISTED
NASDAQ
Healthcare Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Europe and Latin America
News Preview
PLEASANTON, Calif., Jan. 22, 2026 /PRNewswire/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Definitive Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
HCTI
LISTED
NASDAQ
Healthcare Triangle, Inc. Signs Definitive Agreement with Teyame AI LLC which is forecasted to generate $38M in incremental NTM Revenue and incremental NTM EBITDA of $5M in addition to expanding its SaaS Footprint in Europe and Latin America
News Preview
PLEASANTON, Calif., Jan. 22, 2026 /CNW/ -- Healthcare Triangle, Inc. (Nasdaq: HCTI) ("HCTI" or the "Company"), a leader in digital transformation solutions for healthcare and life sciences, today announces that it has entered into an Definitive Agreement with Teyame AI LLC, a St Kitts and Nevis corporation ("Teyame"), as part of its planned acquis...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
22.01.2026
GH
LISTED
NASDAQ
Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for BRAFTOVI® (encorafenib) Combination in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
News Preview
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
CORT
LISTED
NASDAQ
Overall Survival Primary Endpoint Met in Corcept’s Pivotal Phase 3 ROSELLA Trial of Relacorilant in Patients with Platinum-Resistant Ovarian Cancer
News Preview
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
GENI
LISTED
NYSE
Genius Sports Launches BetVision for Tennis in Partnership With Infront to Enhance Live Betting Experiences
News Preview
Genius Sports Limited (“Genius Sports”) (NYSE:GENI) has launched BetVision for Tennis in time for the ongoing Australian Open, enhancing the live betting experience for sportsbook customers worldwide.
BetVision transforms the live betting experience by combining low latency live streams with integrated betslips, official game stats and micro mar...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
PRVA
LISTED
NASDAQ
Privia Health to Report Fourth Quarter 2025 Results on Thursday, February 26
News Preview
ARLINGTON, Va., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth-quarter and twelve-month periods ended December 31, 2025 before market open on Thursday, February 26, 2026....
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
302440
LISTED
KOE
SK bioscience, MSD, and Hilleman Laboratories Advance Zaire ebolavirus Vaccine Development with CEPI Funding
News Preview
CEPI to provide up to USD 30 million to support development of MSD's Zaire ebolavirus vaccineCollaboration addresses manufacturing complexity and cold-chain challenges to improve yield and thermostabilityPartnership aims to expand affordable and sustainable vaccine access in low- and middle-income countriesINCHEON, South Korea, Jan. 22, 2026 /PRNe...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
ELAN
LISTED
NYSE
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2025 Financial Results Announcement
News Preview
INDIANAPOLIS, Jan. 22, 2026 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will announce its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026. Elanco will also conduct a conference call on that day with the investment community and media to further detail the company's performance....
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
CVS
LISTED
NYSE
CVS Health® makes health insurance simpler and more affordable for Americans
News Preview
HARTFORD, Conn., Jan. 22, 2026 /PRNewswire/ -- CVS Health® today announced key milestones in its ongoing effort to make health care simpler and more affordable for American consumers.
"Our ambition is to be America's most trusted hea...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
CNC
LISTED
NYSE
Superior HealthPlan Names CommUnityCare and Dell Children's as First Austin Providers to Earn Foster Care Distinction
News Preview
Austin-based Superior HealthPlan now has thirteen Foster Care Centers of Excellence in Texas AUSTIN, Texas, Jan. 22, 2026 /PRNewswire/ -- Superior HealthPlan ("Superior"), a leading managed care organization in Texas and a Centene company (NYSE: CNC), has designated CommUnityCare Health Centers and Dell Children's Medical Group Primary Care Pediat...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
TAK
LISTED
NYSE
Takeda Announces U.S. Availability of GAMMAGARD LIQUID ERC, the Only Ready-to-Use Liquid Immunoglobulin Therapy with Low Immunoglobulin A (IgA) Content1
News Preview
Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency (PI). GAMMAGARD LIQUID ERC is a liquid immunoglob...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
HNSA
LISTED
STO
Hansa Biopharma has won the 2025 SwedenBIO Award
News Preview
LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm on 21 January, where Hansa was selected as the winner among the many nominated companies.
Since its in...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
HNSA
LISTED
STO
Hansa Biopharma has won the 2025 SwedenBIO Award
News Preview
LUND, Sweden, Jan. 22, 2026 /PRNewswire/ -- Hansa Biopharma AB, "Hansa" (Nasdaq Stockholm: HNSA), today announced that the company has been awarded the prestigious 2025 SwedenBIO Award. The award was presented at the SwedenBIO Summit in Stockholm on 21 January, where Hansa was selected as the winner among the many nominated companies.
Since its in...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
CERS
LISTED
NASDAQ
DRK Blood Donation Service Baden-Württemberg – Hessen Starts INITIATE Study to Evaluate Pathogen-Inactivated Platelet Concentrates Treated with Cerus’ INTERCEPT™ Blood System in Routine Clinical Practice
News Preview
Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Ba...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
COR
LISTED
NYSE
Cencora Elects Ellen Cooper to Its Board of Directors
News Preview
Cencora, Inc. (NYSE: COR) today announced that its Board of Directors has elected Ellen Cooper as a new independent director, effective January 20, 2026.
Ms. Cooper is the Chairman, President and Chief Executive Officer of Lincoln Financial. Prior to assuming the role of CEO in May 2022, she served as Executive Vice President, Chief Investment O...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
AIAI
LISTED
CSE
NetraMark Engages LodeRock Advisors for Strategic Investor Relations and Capital Markets Communications Services
News Preview
TORONTO, Jan. 22, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that it has retained LodeRock Advisors Inc. (...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
ATX
LISTED
ASX
NARMAFOTINIB Large-Scale Manufactre Complete
News Preview
Successful completion of the first large-scale manufacture of narmafotinib which produced approx. 13 kg of drug...
Themefolio
Profiler
Peergroup
© PR Newswire
22.01.2026
ABT
LISTED
NYSE
Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook
News Preview
Fourth-quarter GAAP diluted EPS of $1.01; adjusted diluted EPS of $1.50 reflects growth of 12 percentFull-year 2025 GAAP diluted EPS of $3.72; adjusted diluted EPS of $5.15 reflects growth of 10 percentAbbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%Abbott projects full-year 2026 adjusted diluted EPS of $5.55...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
SXTP
LISTED
NASDAQ
60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention
News Preview
60 Degrees Pharma partners with Runway Health to give international travelers direct telehealth access to once-weekly ARAKODA for malaria prevention....
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
UTHR
LISTED
NASDAQ
United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors
News Preview
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Kevin J. Tracey, M.D., to its Board on January 21, 2026.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260122174254/en/Kevin Tracey was recentl...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
BEAT
LISTED
NASDAQ
HeartBeam Appoints Bryan Humbarger as Chief Commercial Officer
News Preview
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced the appointment of Bryan Humbarger as Chief Commercial Officer, effective January 22, 2026. In this newly created role, Mr. Humbarger will lead commercial strategy and execution across the Compan...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
JANX
LISTED
NASDAQ
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
News Preview
Janux Therapeutics, Inc. (Nasdaq: JANX) (“Janux”), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technologies to its Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms, today announced...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
TARA
LISTED
NASDAQ
Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium
News Preview
NEW YORK, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that updated interim data from the cohort of BCG-Unresponsive non-muscle invasive bladder cancer (NMIBC) patients in the ongoing Phase 2...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
IXHL
LISTED
NASDAQ
Incannex Healthcare Announces Formation of Clinical Advisory Board for PSX-001 Program
News Preview
Incannex Healthcare formed a Clinical Advisory Board to guide PSX-001 as it advances into its next phase of clinical and regulatory development....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
MRMD
LISTED
CSE
MariMed Launches Hemp-Derived THC Products Under its Vibations™ Brand in Rhode Island
News Preview
MariMed's hemp-derived THC version of its Vibations drink mix brand has launched in Rhode Island....
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
MDCX
LISTED
TSX
Medicus Pharma Ltd. Announces Amendment to LifeArc License Improving Teverelix® Long-Term Economic and Development Profile
News Preview
Amendment reduces and simplifies royalty structure on Teverelix® from ~4% to 2% while preserving global rights and IP control...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
IVVD
LISTED
NASDAQ
Invivyd Announces Partnership with World Champion Skier Lindsey Vonn to Educate Americans on Antibodies and Disease Prevention
News Preview
NEW HAVEN, Conn., Jan. 22, 2026 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced a partnership with renowned ski champion Lindsey Vonn to elevate public understanding of antibodies, one of the most important parts of the immune system, and their role in preventing disease. A national multimedia education campaign is planned to lau...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
SVA
LISTED
NASDAQ
SINOVAC Announces Nasdaq Hearings Panel Grants Continued Listing
News Preview
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request to continue its listing on the Nasdaq Stock Market, subject to stated conditions focused on timely completion of its financial aud...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
TLRY
LISTED
TSX
SweetWater Introduces Big Trip Double IPA: A Bold New Craft Beer
News Preview
The Daytrip IPA series grows with Big Trip - a high-ABV brew full of flavor from the Southeast’s leading craft brand The Daytrip IPA series grows with Big Trip - a high-ABV brew full of flavor from the Southeast’s leading craft brand...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
VANI
LISTED
NASDAQ
Vivani Subsidiary Cortigent to Present Orion System’s Advanced Brain Implant Technology in Poster Session at NANS 2026
News Preview
Cortigent is a leading developer of brain interface devices based on precision neurostimulation technology ...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
TLRY
LISTED
TSX
Tilray Medical Strengthens Italian Market Presence with the Launch of Tilray Medical Italia and Expanded Medical Cannabis Portfolio
News Preview
NEW YORK and SAVONA, Italy, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, today announced a strategi...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
GLSI
LISTED
NASDAQ
Greenwich LifeSciences Announces FDA Approves Use of Commercially Manufactured GP2 in FLAMINGO-01
News Preview
STAFFORD, Texas, Jan. 22, 2026 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today provided the following update on the use of comm...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2026
AFX
LISTED
XETR
Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved
News Preview
Q1 FY 2025/26 earnings clearly below past year - FY 2025/26 guidance will likely not be achieved
Jena, January 22, 2026
In the first 3 months of fiscal year (FY) 2025/26 ending December 31, 2025, Carl Zeiss Meditec AG (ISIN: DE0005313704) recorded preliminary revenue of € 467 million (prior year: € 490 million). The revenue decline was ma......
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2026
AFX
LISTED
XETR
Q1 GJ 2025/26 Ergebnis deutlich unter Vorjahr - Prognose für GJ 2025/26 wird voraussichtlich nicht erreicht
News Preview
Q1 GJ 2025/26 Ergebnis deutlich unter Vorjahr - Prognose für GJ 2025/26 wird voraussichtlich nicht erreicht
Jena, 22. Januar 2026
In den ersten drei Monaten des Geschäftsjahres (GJ) 2025/26 bis zum 31. Dezember 2025 erzielte die Carl Zeiss Meditec AG (ISIN: DE0005313704) einen vorläufigen Umsatz von 467 Mio. € (Vorjahr: 490 Mio. €). Der U......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2026
JAGX
LISTED
NASDAQ
Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi
News Preview
Jaguar has received the initial $16M payment related to the company's recently executed US out-license agreement for Mytesi® and Canalevia®-CA1, which has the potential to provide Jaguar up to an additional $22M with milestones and other potential future paymentsNear-term milestones for intestinal failure program buttressed by groundbreak...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2026
IGC
LISTED
XASE
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
News Preview
- Multi-Specialty CNS Research Center Strengthens Trial Execution and Patient Diversity in Alzheimer's Agitation Study - POTOMAC, MD / ACCESS Newswire / January 22, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage pharmaceutical company leveraging Artificial Intelligence ("AI") to...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2026
ASBP
LISTED
NASDAQ
Aspire Biopharma Scales Consumer Division with Delivery of Two Million BUZZ BOMB(TM) Units Featuring Modernized Brand Identity
News Preview
Strategic inventory of 100,000 20-packs now available to meet increasing demand for rapid-onset sublingual caffeine technology ESTERO, FL / ACCESS Newswire / January 22, 2026 / Aspire Biopharma Holdings, Inc. (NASDAQ:ASBP), a leader in innovative patent-pending sublingual delivery technologies, today announced it has taken delivery of two million u...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
45680
LISTED
XJPX
Daiichi Sankyo Appoints New Leadership at the Daiichi Sankyo Translational Research Center Europe
News Preview
Daiichi Sankyo (TSE:4568) has appointed Veronika Rozehnal, Ph.D., to succeed Jürgen Müller, Ph.D., as the Head of the Translational Research Center Europe.
Dr. Jürgen Müller will retire after nearly 30 years of research work at Daiichi Sankyo. Under his leadership, the Translational Research Center Europe, previously called the Tissue and Cell R...
Themefolio
Profiler
Peergroup
© BusinessWire
22.01.2026
GALD
LISTED
XWSX
IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry’s Broadest Injectable Aesthetics Portfolio
News Preview
Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leaders...
Themefolio
Profiler
Peergroup
© EQS Newswire
22.01.2026
GALE
LISTED
SIX
sales increase to over CHF 4 billion
News Preview
Press releaseAd hoc announcement pursuant to Art. 53 LR
Sales up by 5.5% to CHF 4,135.6 million
Broad-based growth – with all business areas contributing
Strong pharmacy business driven by prescription medicines and dietary supplements
Continuous growth in wholesale
New “Diagnostics” area contributes 1% to sales growth
EBIT1 guidance with 10-......
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2026
ZOMDF
LISTED
OTC
Zomedica Enters Contract Manufacturing and Services Agreement with Rahm Sensor Development to Expand Revenue Streams Beyond Animal Health
News Preview
Agreement leverages existing infrastructure to add contract-based revenue, improve asset utilization, support long-term cash flow and create shareholder value through diversified markets ANN ARBOR, MI / ACCESS Newswire / January 22, 2026 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), an animal health company offer...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
22.01.2026
IMRN
LISTED
NASDAQ
Emerging Growth Research Issues Flash Update on Immuron Limited, Maintains Buy-Extended Rating and $3.50 Price Target
News Preview
NEW YORK CITY, NY / ACCESS Newswire / January 22, 2026 / Emerging Growth Research today released a Flash Research Update on Immuron Limited (Nasdaq:IMRN), maintaining its Buy-Extended rating and 12-month price target of $3.50 following the Company's release of first-half fiscal year 2026 operating results.The Flash Report notes that Immuron reporte...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
AXGN
LISTED
NASDAQ
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
News Preview
ALACHUA, Fla. and TAMPA, Fla., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Axogen, Inc. (Nasdaq: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today announced the pricing of an upsized underwritten public offering of 4,000,000 shares of its common stock at a price to the p...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
CRVS
LISTED
NASDAQ
Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
News Preview
SOUTH SAN FRANCISCO, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an upsized underwritten public offering of 7,900,677 shares of its common stock at a price to the public of $22.15 per share. Gross proceeds from the underwritten pu...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
BIOA
LISTED
NASDAQ
BioAge Announces Pricing of Upsized $115.0 Million Public Offering
News Preview
EMERYVILLE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (Nasdaq: BIOA) ("BioAge", “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced the pricing of its upsized underwritten public offering of 5,897,435...
Themefolio
Profiler
Peergroup
© Globe Newswire
22.01.2026
ERAS
LISTED
NASDAQ
Erasca Announces Pricing of Upsized Public Offering of Common Stock
News Preview
SAN DIEGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced the pricing of an upsized public offering of 22,500,000 shares of its common stock. Th...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2026
GILD
LISTED
NASDAQ
New England Journal of Medicine Publishes Phase 3 ASCENT-04/KEYNOTE-D19 Results Supporting Trodelvy® Plus Keytruda® as a Potential New Standard of Care in First-line PD-L1+ Metastatic Triple-negative Breast Cancer
News Preview
Gilead Sciences, Inc. (Nasdaq: GILD) today announced The New England Journal of Medicine (NEJM) published the full results from the positive Phase 3 ASCENT-04/KEYNOTE-D19 study evaluating the combination of Trodelvy® (sacituzumab govitecan-hziy) plus Keytruda® (pembrolizumab) in first-line PD-L1+ (CPS ≥10) metastatic triple-negative breast cancer...
Themefolio
Profiler
Peergroup
© BusinessWire
21.01.2026
BAX
LISTED
NYSE
Baxter to Host Fourth-Quarter 2025 Financial Results Conference Call for Investors
News Preview
Baxter International Inc. (NYSE:BAX), a leading global medtech company, will host a conference call to discuss its fourth-quarter 2025 financial results on Thursday, February 12, 2026 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://registrations.events/direct/Q4I81994118 to pre-register for the cal...
Themefolio
Profiler
Peergroup
© Newsfile
21.01.2026
OPTI
LISTED
CSE
Early Warning Press Release in Accordance with National Instrument 62-103
News Preview
Vancouver, British Columbia--(Newsfile Corp. - January 21, 2026) - Cathay Visions Enterprises Ltd. (the "Acquiror") acquired 102,500 common shares (each a "Common Share") of Optimi Health Corp. (the "Issuer") at a price of $0.32 in the public market. Prior to giving effect to the foregoing acquisition of Common Shares, the Acquiror owned and/or had...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
